logo
logo

Oviva Therapeutics, A Cambrian Biopharma *Pipeco, Announces Seed Financing And Exclusive License With Massachusetts General Hospital To Develop Therapeutics To Extend Healthspan In Women

Oviva Therapeutics, A Cambrian Biopharma *Pipeco, Announces Seed Financing And Exclusive License With Massachusetts General Hospital To Develop Therapeutics To Extend Healthspan In Women

05/19/22, 9:01 AM
Round Type
seed
Oviva Therapeutics, Inc. (Oviva), the women's health biotech company and a Cambrian Biopharma *PipeCo, today announced an in-licensing agreement with Massachusetts General Hospital (MGH) of a family of patents, as well as $11.5 million in Seed funding, to develop first-in-class therapeutics to improve healthspan – the period of life spent in good health - in women. Oviva Therapeutics addresses the vast unmet need in women's health by expanding funding, research, and clinical development of treatments addressing female physiology, beginning with a focus on ovarian aging.

Company Info

Company
Oviva Therapeutics
Additional Info
Oviva Therapeutics, Inc. is leading a movement to improve women's experience of aging through biomedical research, development and advocacy. Oviva addresses the vast unmet need in women's health by expanding funding, research, and clinical development, and is currently developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan.
G2 High Performer Badge

Recognized as a G2 High Performer

Unlock Real-Time Insights to Close More Deals

Stay ahead with lightning-fast updates on funding rounds, acquisitions, executive hires, and more—all powered by AI-driven tools.